ArticlePharmaceutical research2013
(89)Zr-labeled paramagnetic octreotide-liposomes for PET-MR imaging of cancer.
Article in Pharmaceutical research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 86 citations in OpenAlex.
- Nanomedicine-Based Strategies for Multiple Myeloma Therapy.International journal of nanomedicine · 2026Review
- Strategic Objectives of Nanotechnology-Driven Repurposing in Radiopharmacy-Implications for Radiopharmaceutical Repurposing (Beyond Oncology).Pharmaceutics · 2025Review
- Nanoparticles labeled with gamma-emitting radioisotopes: an attractive approach for in vivo tracking using SPECT imaging.Drug delivery and translational research · 2023Review
- Radiolabeled nanomaterial for cancer diagnostics and therapeutics: principles and concepts.Cancer nanotechnology · 2023Review
- Pathogenesis and treatment of multiple myeloma.MedComm · 2022Review
- PET Imaging of Small Extracellular VesiclesBioconjugate chemistry · 2022Article
- Recent Advances in Gadolinium Based Contrast Agents for Bioimaging Applications.Nanomaterials (Basel, Switzerland) · 2021Review
- Peptide-Conjugated Nano Delivery Systems for Therapy and Diagnosis of Cancer.Pharmaceutics · 2021Review
- Metallofluorocarbon Nanoemulsion for Inflammatory Macrophage Detection via PET and MRI.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Targeted PET/MRI Imaging Super Probes: A Critical Review of Opportunities and Challenges.International journal of nanomedicine · 2021Review
- Image-guided mathematical modeling for pharmacological evaluation of nanomaterials and monoclonal antibodies.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020Review
- Simultaneous in vivo PET/MRI using fluorine-18 labeled FeEJNMMI research · 2020Article
- Radio-metal cross-linking of alginate hydrogels for non-invasive in vivo imaging.Biomaterials · 2020Article
- Osteotropic Radiolabeled Nanophotosensitizer for Imaging and Treating Multiple Myeloma.ACS nano · 2020Article
- PET Imaging of Liposomal Glucocorticoids usingTheranostics · 2020Article
- Radiolabeled PET/MRI Nanoparticles for Tumor Imaging.Journal of clinical medicine · 2019Review
- In Vivo Tracking of Tissue Engineered Constructs.Micromachines · 2019Review
- Nuclear imaging of liposomal drug delivery systems: A critical review of radiolabelling methods and applications in nanomedicine.Advanced drug delivery reviews · 2019Review
- Multimodality Imaging Agents with PET as the Fundamental Pillar.Angewandte Chemie (International ed. in English) · 2019Review
- Toxicological status of nanoparticles: What we know and what we don't know.Chemico-biological interactions · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
purposeDual-modality PET/MR platforms add a new dimension to patient diagnosis with high resolution, functional, and anatomical imaging. The full potential of this emerging hybrid modality could be realized by using a corresponding dual-modality probe. Here, we report pegylated liposome (LP) formulations, housing a MR T(1) contrast agent (Gd) and the positron-emitting (89)Zr (half-life: 3.27 days), for simultaneous PET and MR tumor imaging capabilities.
methods(89)Zr oxophilicity was unexpectedly found advantageous for direct radiolabeling of preformed paramagnetic LPs. LPs were conjugated with octreotide to selectively target neuroendocrine tumors via human somatostatin receptor subtype 2 (SSTr2). (89)Zr-Gd-LPs and octreotide-conjugated homolog were physically, chemically and biologically characterized.
results(89)Zr-LPs showed reasonable stability over serum proteins and chelator challenges for proof-of-concept in vitro and in vivo investigations. Nuclear and paramagnetic tracking quantified superior SSTr2-recognition of octreotide-LP compared to controls.
conclusionsThis study demonstrated SSTr2-targeting specificity along with direct chelator-free (89)Zr-labeling of LPs and dual PET/MR imaging properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.